Literature DB >> 3166364

Synthesis and biological properties of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid.

D H Boschelli1, S Webber, J M Whiteley, A L Oronsky, S S Kerwar.   

Abstract

The synthesis of the antifolate 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF) has been modified. It is prepared from 2-acetamido-6-formyl-4(3H)-pyrido[2,3-b]pyrimidone and [P-(N-[1,3-bis(ethoxycarbonyl)propan-1-yl]aminocarbonyl)] phenylmethyl]-triphenylphosphonium bromide. The synthesis proceeds via a sodium hydride promoted Wittig condensation in 1-methyl-2-pyrrolidone followed by catalytic reduction, mild base hydrolysis, and acid precipitation of the product. Synthesis of DDATHF is achieved in a total of seven steps from commercially available reagents. DDATHF is transported effectively into CCRF-CEM cells and inhibits growth of both human (CEM) and murine (L1210) cells in culture. Studies reported here support the view that methotrexate and DDATHF are transported via a shared transport mechanism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3166364     DOI: 10.1016/0003-9861(88)90369-4

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  3 in total

1.  Synergy between 5,10-dideaza-5,6,7,8-tetrahydrofolic acid and methotrexate in mice bearing L1210 tumors.

Authors:  K Ferguson; D Boschelli; P Hoffman; A Oronsky; J Whiteley; S Webber; J Galivan; J Freishiem; J Hynes; S S Kerwar
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  A simplified and efficient synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF).

Authors:  E C Taylor; R Chaudhari; K Lee
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 3.  Folic Acid Antimetabolites (Antifolates): A Brief Review on Synthetic Strategies and Application Opportunities.

Authors:  Igor S Kovalev; Grigory V Zyryanov; Sougata Santra; Adinath Majee; Mikhail V Varaksin; Valery N Charushin
Journal:  Molecules       Date:  2022-09-22       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.